Switching to a second TNF inhibitor in inflammatory bowel disease may raise the risk for immune-mediated inflammatory ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as Lynk Pharmaceuticals), a clinical stage innovative drug ...

Vividion publishes manuscript detailing the discovery and optimization of VVD-214, the company’s covalent inhibitor of WRN.

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Modern medical breakthroughs save lives in ways that feel miraculous, showing how faith and science can work together as ...

Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...

Investigators examine the effectiveness of TNF inhibitors on pregnant women and their risk of infection outcomes.

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...